



an Open Access Journal by MDPI

New Molecular Insights into the Pathogenesis and Drug Development of Neurodegenerative Diseases

Guest Editors:

Dr. Aifang Cheng

Faculty of Health Sciences,
University of Macau, Taipa,
Macau

Dr. Beika Zhu

Department of Pediatrics,
University of California, San
Francisco, CA, USA

Deadline for manuscript
submissions:

31 July 2024

Message from the Guest Editors

The prevalence of neurodegenerative diseases is rapidly increasing with the aging trend of global populations, severely threatening human health and creating a societal burden; existing drugs in the market temporarily relieve symptoms but cannot prevent disease progression. Therefore, the development of more effective drugs for neurodegenerative diseases using efficient strategies has become a pressing need. One of the challenges for drug development is the incomplete understanding of the underlying mechanisms of disease pathogenesis.

This Special Issue aims to collect high-quality papers featuring emerging research areas in neurodegenerative diseases, with a particular emphasis on the cellular and molecular mechanisms of disease pathogenesis. It also highlights novel drug discovery targeting neurodegeneration, mode of action studies on drug leads, and pharmacological evaluations of different models. Overall, we hope that this Special Issue will provide a theoretical and technical basis for further preclinical and clinical studies, as well as promote the translational application of valuable candidates as potential therapeutic agents in treating neurodegenerative diseases.



mdpi.com/si/181330

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)